Spermine blocks iron-driven cell death
In Japanese, there is a word: shinrin-yoku. It means “forest bathing”—not swimming in trees, but absorbing the atmosphere of a forest. In German, Waldeinsamkeit describes the feeling of being alone in the woods. In Portuguese, saudade is a longing for something that might not return.
But there is no word in any language for what happens when iron inside your cells turns against you. That silence is about to break.
For decades, scientists knew that iron was essential. Every red blood cell needs it. Every breath you take depends on it. Iron carries oxygen through your veins. Without it, you die within minutes.
But iron has a dark side.
Inside your cells, iron can rust. Not like a nail in the rain, but chemically. When iron reacts with fats in your cell membranes, it creates a chain reaction of destruction. The membranes break. The cell leaks. The cell dies.
In 2012, researchers at Columbia University led by Dr. Scott Dixon gave this process a name: ferroptosis. From the Latin ferrum for iron, and the Greek ptosis for falling. Iron falling. Cell death by iron.
The discovery changed medicine. Suddenly, doctors understood why some cancer cells refused to die. They had built shields against ferroptosis. And why some heart attacks caused more damage than expected. Iron was flooding the injured tissue, turning a small wound into a catastrophe.
But there was a hole in the knowledge. A gap so large it felt like a canyon.
What controls ferroptosis? What decides when iron attacks and when it stays quiet? The body must have a natural brake. Something that tells iron: Stop. Not here. Not now.
For thirteen years, no one found it.
The search began in the liver. Specifically, in hepatocellular carcinoma—the most common form of liver cancer. It kills nearly 800,000 people every year. And it is notoriously resistant to treatment.
A team of researchers from Sun Yat-sen University in China, Institut Curie in France, and the University of Texas Southwestern Medical Center in the United States started asking a different question [1][2][3]. Not how do cancer cells resist ferroptosis, but what do they use to resist it.
They looked at the metabolism of cancer cells. Cancer cells are hungry. They eat constantly. They consume glucose, glutamine, and other nutrients at rates that would poison normal cells. But cancer cells don’t just eat—they transform what they eat into something else.
The team analyzed metabolomics data from hundreds of liver tumor samples. They tracked every molecule, every chemical reaction. They looked for patterns.
One molecule kept appearing. A small, simple compound with a strange name: spermine.
Spermine was discovered in 1678 by Antonie van Leeuwenhoek, the same Dutch scientist who first saw bacteria under a microscope. He found crystals in human semen and named it accordingly. For centuries, scientists thought spermine was just a waste product. Something the body made and then flushed out.
They were wrong.
Spermine belongs to a family called polyamines. These are small molecules that cells use for growth, division, and protection. They are found in every living thing on Earth—from bacteria to redwood trees to human brains.
But the researchers noticed something odd. In liver cancer cells, spermine levels were sky-high. The cancer cells were making massive amounts of it. Why would a cancer cell waste energy on a waste product?
It wasn’t waste. It was armor.
The team used stable isotope tracing—a technique where they feed cells nutrients with tagged atoms, then follow where those atoms go. They watched as cancer cells took glutamine, an amino acid, and turned it into spermine through a previously unknown pathway.
The key player was an enzyme called ALDH18A1. Think of it as a factory foreman. It directs the assembly line that builds spermine from glutamine. Without ALDH18A1, the factory shuts down.
But the real discovery came next.
They mixed pure spermine with iron in a test tube. Using biophysical studies—spectroscopy, calorimetry, and crystallography—they watched what happened.
Spermine wrapped around the iron like a hand closing around a hot coal. It bound the iron so tightly that the iron could no longer react with fats. The rusting stopped. The ferroptosis was blocked.
Spermine is an endogenous iron chelator. A natural iron trap. The body’s own brake on cell death.
The implications rippled outward like a stone dropped in still water.
If cancer cells use spermine to protect themselves, then stopping spermine production should make them vulnerable. The researchers tested this. They used genetic knockout—removing the ALDH18A1 gene from cancer cells. They used short hairpin RNA delivered by adeno-associated virus—a method to silence the gene temporarily. They used a small molecule inhibitor called YG1702—a drug that blocks ALDH18A1 activity.
Every method worked.
Without ALDH18A1, cancer cells could not make spermine. Without spermine, iron ran free. The cells died by ferroptosis. In mice with liver cancer, blocking ALDH18A1 shrank tumors. It prevented new tumors from forming. It worked against both spontaneous cancers and those triggered by chemical carcinogens.
But the story has two sides.
If spermine blocks ferroptosis, then adding spermine might protect healthy cells from iron damage. This matters most in ischaemia–reperfusion injury.
Imagine a heart attack. Blood stops flowing to part of the heart. Cells start to die from lack of oxygen. Then doctors reopen the artery. Blood rushes back in. But with the blood comes iron. The sudden flood of iron triggers ferroptosis, killing cells that might have survived.
The same thing happens in strokes, in kidney transplants, in intestinal surgery.
The researchers tested spermine as a treatment. In mice, they induced ischaemia–reperfusion injury in the liver, intestine, and kidneys. Then they gave the mice spermine supplements.
The results were striking. Spermine protected all three tissues. It reduced cell death. It preserved organ function. The iron trap worked exactly as predicted.
This is not a single discovery. It is a bridge between fields that rarely speak to each other.
Metabolism researchers study how cells make energy. Cell death researchers study how cells die. Cancer researchers study uncontrolled growth. Transplant surgeons study organ preservation. Each group has its own journals, its own conferences, its own language.
This study connects them.
The ALDH18A1-spermine-iron axis is a metabolic circuit. A loop that controls whether a cell lives or dies. Cancer cells hijack it to survive. Healthy cells use it to protect themselves. Understanding the circuit means understanding how to flip the switch.
Other labs are already working on related pieces. At the University of Pittsburgh, researchers are developing drugs that trigger ferroptosis in drug-resistant cancers [4]. At the Weizmann Institute in Israel, scientists are mapping all the natural iron chelators in the human body [5]. At Kyoto University, teams are testing polyamine supplements for heart attack recovery [6].
This study gives them a target. A specific enzyme. A specific molecule. A specific pathway.
The word that didn’t exist now has a mechanism.
Ferroptosis is no longer just a process. It is a process with a dimmer switch. Turn it up to kill cancer cells. Turn it down to protect healthy tissue.
The researchers published their findings in Nature on June 3, 2026. The paper lists 18 authors from institutions across China, France, and the United States. The lead corresponding author is Jun Li from Sun Yat-sen University [1].
But the work is not finished.
The YG1702 inhibitor needs to be tested in humans. The spermine supplements need clinical trials for transplant patients. The ALDH18A1 gene needs to be examined in other cancers—breast, lung, colon. The iron trap might work differently in different tissues.
And there is a deeper question: If the body makes its own ferroptosis blocker, why does it not protect everyone? Why do some people develop cancer while others don’t? Why do some heart attacks cause massive damage while others heal?
The answer might lie in individual differences in spermine production. In genetic variations of ALDH18A1. In diet, because glutamine comes from food.
By the year 2030, this discovery will have changed how we treat three major killers: cancer, heart disease, and organ failure. The number is not a guess. It is based on the timeline of drug development. Phase I trials for YG1702 are expected to begin in 2028. Phase II results will arrive by 2030.
If successful, the first patients to benefit will be those with liver cancer who have run out of options. Then kidney transplant recipients. Then heart attack survivors.
And all of it started with a word that didn’t exist fourteen years ago.
Now it has a name, a mechanism, and a cure waiting in the wings.